Reply to "Letter responding to performance of updated piperacillin-tazobactam breakpoints on the MicroScan antimicrobial susceptibility testing system".
作者信息
Humphries Romney M, Abbott April N, Alby Kevin, Dien Bard Jennifer, Harrington Amanda T, Mathers Amy J, Simner Patricia J
机构信息
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center , Nashville, Tennessee, USA.
Laboratory Medicine, Deaconess Health System , Evansville, Indiana, USA.
出版信息
J Clin Microbiol. 2023 Nov 21;61(11):e0069123. doi: 10.1128/jcm.00691-23. Epub 2023 Oct 12.
Abstract
摘要
相似文献
1
Reply to "Letter responding to performance of updated piperacillin-tazobactam breakpoints on the MicroScan antimicrobial susceptibility testing system".对《关于更新的哌拉西林-他唑巴坦折点在MicroScan抗菌药物敏感性检测系统上的性能的回复信》的回复
J Clin Microbiol. 2023 Nov 21;61(11):e0069123. doi: 10.1128/jcm.00691-23. Epub 2023 Oct 12.
2
The Editors' reply to "Letter responding to performance of updated piperacillin-tazobactam breakpoints on the MicroScan antimicrobial susceptibility testing system".编辑对《关于更新的哌拉西林-他唑巴坦折点在MicroScan抗菌药物敏感性检测系统上的性能的回复信》的回复
J Clin Microbiol. 2023 Nov 21;61(11):e0069223. doi: 10.1128/jcm.00692-23. Epub 2023 Oct 12.
3
Letter responding to performance of updated piperacillin-tazobactam breakpoints on the MicroScan antimicrobial susceptibility testing system.关于更新后的哌拉西林-他唑巴坦药敏断点在MicroScan抗菌药物敏感性检测系统上性能表现的回复函
J Clin Microbiol. 2023 Nov 21;61(11):e0049723. doi: 10.1128/jcm.00497-23. Epub 2023 Oct 12.
4
Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of , , and Complex.多中心评估新 Etest 梯度扩散法检测产 ESBL 肠杆菌科细菌对哌拉西林-他唑巴坦药敏试验的准确性
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01042-19.
5
Evaluation of Piperacillin-Tazobactam Testing against by the Phoenix, MicroScan, and Vitek2 Tests Using Updated Clinical and Laboratory Standards Institute Breakpoints.采用更新后的临床和实验室标准协会折点，评价 Phoenix 法、MicroScan 法和 Vitek2 法检测哌拉西林-他唑巴坦对的效果。
J Clin Microbiol. 2023 Feb 22;61(2):e0161722. doi: 10.1128/jcm.01617-22. Epub 2023 Jan 31.
6
Strategies for Updating Piperacillin-Tazobactam Breakpoints.哌拉西林-他唑巴坦折点更新策略。
J Clin Microbiol. 2023 Apr 20;61(4):e0004223. doi: 10.1128/jcm.00042-23. Epub 2023 Mar 15.
7
Disk Correlates for Revised Clinical and Laboratory Standards Institute Piperacillin-Tazobactam MIC Breakpoints.针对修订后的临床和实验室标准协会哌拉西林-他唑巴坦最低抑菌浓度（MIC）断点的磁盘相关性
J Clin Microbiol. 2022 May 18;60(5):e0024322. doi: 10.1128/jcm.00243-22. Epub 2022 Apr 21.
8
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.头孢吡肟/他唑巴坦与其他他唑巴坦联合用药针对难治革兰氏阴性菌的比较。
Int J Antimicrob Agents. 2021 May;57(5):106318. doi: 10.1016/j.ijantimicag.2021.106318. Epub 2021 Mar 11.
9
Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.大肠杆菌序列型131临床分离株对哌拉西林-他唑巴坦的异质性耐药
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01923-17. Print 2018 Jan.
10
activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non- and collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020.对来自西欧血流感染、腹腔内感染和尿路感染患者的哌拉西林/他唑巴坦耐药和/或美罗培南耐药的非肠杆菌科细菌和肠杆菌科细菌的活性：SMART 2018-2020。
J Med Microbiol. 2023 Feb;72(2). doi: 10.1099/jmm.0.001645.
本文引用的文献
1
Evaluation of Piperacillin-Tazobactam Testing against by the Phoenix, MicroScan, and Vitek2 Tests Using Updated Clinical and Laboratory Standards Institute Breakpoints.采用更新后的临床和实验室标准协会折点，评价 Phoenix 法、MicroScan 法和 Vitek2 法检测哌拉西林-他唑巴坦对的效果。
J Clin Microbiol. 2023 Feb 22;61(2):e0161722. doi: 10.1128/jcm.01617-22. Epub 2023 Jan 31.
2
Evaluation of Piperacillin-Tazobactam ETEST for the Detection of OXA-1 Resistance Mechanism among Escherichia coli and Klebsiella pneumoniae.评估哌拉西林-他唑巴坦 ETEST 检测大肠埃希菌和肺炎克雷伯菌中的 OXA-1 耐药机制。
J Clin Microbiol. 2022 Dec 21;60(12):e0143022. doi: 10.1128/jcm.01430-22. Epub 2022 Nov 23.
Zotero 插件